Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Shanafelt TD, et al. Among authors: laumann k. Cancer. 2013 Jan 15;119(2):363-70. doi: 10.1002/cncr.27719. Epub 2012 Jul 3. Cancer. 2013. PMID: 22760587 Free PMC article. Clinical Trial.
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.
Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Kumar SK, et al. Among authors: laumann k. Blood Cancer J. 2015 Aug 14;5(8):e338. doi: 10.1038/bcj.2015.60. Blood Cancer J. 2015. PMID: 26275080 Free PMC article. Clinical Trial.
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Dispenzieri A, et al. Among authors: laumann k. Blood. 2012 Jun 7;119(23):5397-404. doi: 10.1182/blood-2012-02-413161. Epub 2012 Apr 4. Blood. 2012. PMID: 22493299 Free PMC article. Clinical Trial.
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Ailawadhi S, et al. Among authors: laumann km. Leukemia. 2018 Mar;32(3):719-728. doi: 10.1038/leu.2017.258. Epub 2017 Sep 1. Leukemia. 2018. PMID: 28860655 Clinical Trial.
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Kumar SK, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, Gertz MA, Laumann K, Miceli T, Mahlman M, Bergsagel LP, Hayman SR, Reeder C, Stewart AK, Dispenzieri A, Gastineau DA, Winters JL. Kumar SK, et al. Among authors: laumann k. Bone Marrow Transplant. 2014 Feb;49(2):201-5. doi: 10.1038/bmt.2013.175. Epub 2013 Nov 4. Bone Marrow Transplant. 2014. PMID: 24185588 Free PMC article. Clinical Trial.
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
Dispenzieri A, Tong C, LaPlant B, Lacy MQ, Laumann K, Dingli D, Zhou Y, Federspiel MJ, Gertz MA, Hayman S, Buadi F, O'Connor M, Lowe VJ, Peng KW, Russell SJ. Dispenzieri A, et al. Among authors: laumann k. Leukemia. 2017 Dec;31(12):2791-2798. doi: 10.1038/leu.2017.120. Epub 2017 Apr 25. Leukemia. 2017. PMID: 28439108 Free PMC article. Clinical Trial.
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Reeder CB, et al. Among authors: laumann k. Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30. Br J Haematol. 2014. PMID: 24974945 Free article. Clinical Trial. No abstract available.
Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A. Warsame R, et al. Among authors: laumann k. Blood Cancer J. 2020 Jan 8;10(1):4. doi: 10.1038/s41408-019-0266-9. Blood Cancer J. 2020. PMID: 31913261 Free PMC article.
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R. Kumar SK, et al. Among authors: laumann k. Am J Hematol. 2015 Dec;90(12):1106-10. doi: 10.1002/ajh.24181. Epub 2015 Oct 6. Am J Hematol. 2015. PMID: 26331432 Free article. Clinical Trial.
56 results